

RECEIVED

JUN 25 2002

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Attorney. Docket No. 039322-0226

Applicants: James P. HOEFFLER *et al.*

Title: SINGLE CHAIN MONOCLONAL ANTIBODY FUSION  
REAGENTS THAT REGULATE TRANSCRIPTION *IN*  
*VIVO*

Application No.: 09/939,769

RECEIVED

Filing Date: August 28, 2001

JUL 09 2002

Examiner: Susan Unger

TECH CENTER 1600/2900

Art Unit: 1642

**AMENDMENT TRANSMITTAL**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- [ X ] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a  
Small Entity statement previously submitted.
- [ ] Small Entity statement is enclosed.
- [ X ] The fee required for additional claims is calculated below:

Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims: 51	- 23	= 28	X \$18.00 =	\$504.00
Independents: 7	- 7	= 0	X \$84.00 =	\$0.00
First presentation of any Multiple Dependent Claims:			+ \$280.00 =	\$0.00
			CLAIMS FEE TOTAL: =	\$504.00

- [ ] Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a)  
for the total number of months checked below:

Serial No.: 09/939,769

Attorney Docket No.: 039322-0226

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$400.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$920.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,440.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,960.00	\$0.00
	EXTENSION FEE TOTAL:		\$0.00
	CLAIMS AND EXTENSION FEE TOTAL:		\$504.00
<input checked="" type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$252.00
	TOTAL FEE:		\$252.00

- Please charge Deposit Account No. 19-0741 in the amount of \$252.00. A duplicate copy of this transmittal is enclosed.
- A check in the amount of \$252.00 is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

By   
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date 25 June 2002

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

RECEIVED

JUL 09 2002

TECH CENTER 1600/290

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Attorney. Docket No. 039322-0226

Applicants: James P. HOEFFLER *et al.* #11/c  
Title: SINGLE CHAIN MONOCLONAL ANTIBODY FUSION JM  
REAGENTS THAT REGULATE TRANSCRIPTION *IN VIVO*  
Application No.: 09/939,769 8/12/02  
Filing Date: August 28, 2001  
Examiner: Susan Unger  
Art Unit: 1642

**SUPPLEMENTAL PRELIMINARY AMENDMENT**

Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

07/03/2002 RHPDN 00000011 09939769

01 FC:203

Prior to examination of this application, Applicants respectfully request that the Office enter the following amendments.

**IN THE CLAIMS**

Please cancel claims 8 and 23, without prejudice or disclaimer. In accordance with 37 C.F.R. § 1.121, please substitute claims 1-23 with the following, rewritten version of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

G ↓ 1. (Amended) A method of screening a DNA construct library for a single chain monoclonal antibody fusion reagent capable of binding a transcription associated biomolecule within a host cell, comprising:

C ↓ (a) cloning a first nucleic acid fragment that codes for a DNA-binding domain peptide of a transcription activator into a first expression vector to yield a construct